CHEK2 and cyclic hematopoiesis: Furthermore, 11 patients with a CH-associated mutation in a DDR gene (CHEK2, PPM1D, TP53) had significantly worse overall survival than all other patients (12-month survival: 54.5% [95% CI: 31.8-93.6] vs 72.9% [95% CI: 70.1-75.8], P = .03; Supplementary Figure S2).